Key facts
- This page summarizes Michael Mano's Form 4 filing for Karyopharm Therapeutics Inc. (KPTI).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2025, 16:46.
Michael Mano - 28 Feb 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)
- Reporting relationship
- SVP, General Counsel&Secretary
- Issuer ticker
- KPTI
- Reported as of
- 28 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 16:46:17 UTC
- Prior SEC filing
- 05 Sep 2024
- Next SEC filing
- 06 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Nancy Smith as Attorney-in-Fact for Michael Mano
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Mano filed Form 4 for Karyopharm Therapeutics Inc. (KPTI) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 05 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KPTI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,333
- Change %
- +18%
- Price
- $0.000000
- Shares after
- 21,590
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
KPTI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,250
- Change %
- +10%
- Price
- $0.000000
- Shares after
- 23,840
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KPTI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,666
- Change %
- Price
- $0.000000
- Shares after
- 6,666
- Date
- 28 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,666
- Exercise price
- $7.95
- Footnotes
- F2, F4
KPTI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +4,500
- Change %
- Price
- $0.000000
- Shares after
- 4,500
- Date
- 28 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,500
- Exercise price
- $7.95
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.
Footnote F2
Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
Footnote F3
Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.
Footnote F4
This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.